Non-Hodgkin Lymphoma
News
Novel delivery system could treat MCL
Researchers say they have developed a system for delivering therapy at the site of mantle cell lymphoma (MCL). The system harnesses nanoparticles...
News
Mutations could be therapeutic target for FL
Mutations in the RRAGC gene appear to be an “excellent candidate for therapeutic targeting” in follicular lymphoma (FL), according to...
Conference Coverage
EZH2 inhibitor can produce durable responses
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...
News
Antibody shows promise for treating CLL
Preclinical research suggests a humanized monoclonal antibody called cirmtuzumab (UC-961) might be an effective treatment for chronic lymphocytic...
Conference Coverage
Venetoclax produces deep responses in ultra-high-risk CLL
Photo courtesy of ASH ORLANDO, FL—The pivotal phase 2 study of venetoclax monotherapy in patients with relapsed/refractory 17p-deleted chronic...
Conference Coverage
Surprising finding in upfront use of idelalisib monotherapy
Photo courtesy of ASH ORLANDO, FL—Investigators have observed early fulminant hepatotoxicity in a subset of primarily younger chronic lymphocytic...
Conference Coverage
Combination offers ‘important new option’ for CLL, team says
Photo courtesy of ASH ORLANDO, FL—Idelalisib, the first-in-class PI3Kδ inhibitor, combined with bendamustine and rituximab (BR) for relapsed/...
News
FDA approves rapid-infusion bendamustine
Photo by Bill Branson The US Food and Drug Administration (FDA) has approved the use of Bendeka, a liquid, low-volume (50 mL), 10-minute infusion...
Conference Coverage
Triplet disappoints in follicular lymphoma trial
Photo courtesy of ASH ORLANDO, FL—A 3-drug regimen is likely not worth pursuing as a first-line treatment option for follicular lymphoma (FL),...
Conference Coverage
2nd-gen BTK inhibitor may be safer, team says
ORLANDO, FL—The second-generation BTK inhibitor acalabrutinib (ACP-196) can elicit durable partial responses in patients with chronic lymphocytic...
News
FDA grants KTE-C19 breakthrough designation
The US Food and Drug Administration (FDA) has granted breakthrough designation for the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 as a...